LXRX Stock — Lexicon Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

Lexicon Pharmaceuticals is a biopharmaceutical company devoting most of its resources to the research and development of its most advanced drug candidates and the commercialization of its approved drug INPEFA (sotagliflozin). It is developing sotagliflozin, an orally-delivered small molecule, as a treatment for hypertrophic cardiomyopathy in the pivotal Phase 3 SONATA-HCM trial, and pilavapadin, an orally-delivered small molecule for neuropathic pain that has completed Phase 2 trials.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.78

Market cap

$792.0M

Cash

$183.2M

Enterprise value

$660.7M

Balance sheet

Cash	$183.2M
Debt	$51.9M
Net cash	$131.3M
Enterprise value	$660.7M
Basic shares	445.2M shares
Fully diluted shares	486.6M shares
Fully diluted market cap	$866.2M
Cash per share	$0.41
Quarterly burn	$9.2M
Cash runway	20.7 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

445.0M

Pre-funded warrants

0.0M

Options

25.5M

RSUs

15.5M

Warrants

0.7M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

486.6M

Cap table as of 2026-06-30.

Price history

Loading LXRX daily closes…

Loading price history…

Next catalyst

ZYNQUISTA (sotagliflozin) · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	ZYNQUISTA (sotagliflozin) STENO1 open-label study in type 1 diabetes	Not disclosed	type 1 diabetes	Q4 2026
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	sotagliflozin SONATA-HCM Phase 3 in hypertrophic cardiomyopathy	Phase 3	hypertrophic cardiomyopathy	Q1 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

INPEFA

Approved · Active Modality: oral small molecule

Aliases sotagliflozin

Target SGLT1/SGLT2

Partnerships Viatris (exclusive license ex-US/ex-EU; $25M upfront; up to $12M regulatory and $185M sales milestones; tiered royalties)

Indications

heart failure (to reduce risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits) (Stage not disclosed)
type 2 diabetes mellitus with chronic kidney disease and other cardiovascular risk factors (Stage not disclosed)

Status note Approved in the US and commercially available. Approved May 2023.

sotagliflozin (hypertrophic cardiomyopathy)

Phase 3 · Active Modality: oral small molecule

Target SGLT1/SGLT2

Indications

hypertrophic cardiomyopathy (Stage not disclosed)

Status note SONATA-HCM pivotal Phase 3 trial patient enrollment completed.

ZYNQUISTA

Phase 3 · Active Modality: oral small molecule

Aliases sotagliflozin

Target SGLT1/SGLT2

Indications

type 1 diabetes (Stage not disclosed)

Status note NDA received complete response letters from FDA in March 2019 and December 2024. FDA Notice of Opportunity for Hearing proceedings ongoing. Company preparing to potentially resubmit the NDA if supported by patient exposure and safety data from a third-party-funded investigator-initiated study; FDA indicated that study's design appears adequate to provide safety data on diabetic ketoacidosis incidence.

pilavapadin

Phase 2 · Active Modality: oral small molecule

Aliases LX9211

Target adapter-associated kinase 1 (AAK1)

Partnerships Bristol-Myers Squibb (drug discovery alliance; $5M milestone upon dosing of first patient in a Phase 3 trial of pilavapadin)

Indications

diabetic peripheral neuropathic pain (Stage not disclosed)

Status note Three Phase 2 clinical trials completed (PROGRESS Phase 2b and RELIEF-DPN-1 Phase 2a in DPNP). FDA Fast Track designation for DPNP. Third-party collaboration discussions for Phase 3 development and commercialization underway; company states it lacks sufficient capital for Phase 3 alone.

LX9851

Phase 1 · Active Modality: oral small molecule

Partnerships Novo Nordisk (exclusive worldwide license, March 2025; $45M upfront, $20M milestones achieved Q1 2026; up to $465M regulatory/commercial and $475M sales milestones; tiered royalties)

Indications

obesity (Stage not disclosed)
associated cardiometabolic disorders (Stage not disclosed)

Status note Novo Nordisk is conducting Phase 1 development.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sotagliflozin
Lead indication	Obstructive Cardiomyopathy, Hypertrophic
Lead phase	Phase 3
Active trials	0
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06217302	Phase 3	Recruiting	Collaborator	Alessandro Doria	—	Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Alessandro Doria on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	750,000	no change	0.08%	2026-08-14
Ikarian Capital	164,674	no change	0.06%	2026-08-14
Tang Capital Partners	0	-399,700	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LXRX — Lexicon Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

LXRX — Lexicon Pharmaceuticals Inc.